Wednesday, June 5, 2019 1:45 PM - 2:45 PM BIO International Convention - Philadelphia, PA Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.
4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET In this webinar we: • Highlight the results of the research • Expand on the datapackage used • Discuss the gap between EU and US IP productivity in healthcare • Address the need for IP in the global biotech sector
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.
By CARMEN PAUN 4/9/19, © POLITICO PRO Healthcare U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.
By Duane Schulthess
It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.
The Alliance for Regenerative Medicine (ARM) supports the efforts of the Better Science Better Health IP Consortium
ARM is the leading international advocacy organization representing the gene and cell therapy sector and consists of more than 290 members, including life sciences companies, patient advocacy groups, academic research institutions, and investors.
Register now to receive all the latest news and events.
Our consultancy services
30th December, 2017
Visit our youtube channel to view all of our videos.